BP
ATRS

Ballentine Partners’s Antares Pharma, Inc. ATRS Stock Holding History

Ballentine Partners’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100,000
Closed -$336K – 390
2018
Q3 		$336K Hold
100,000
– – 0.02% 251
2018
Q2 		$258K Hold
100,000
– – 0.01% 274
2018
Q1 		$220K Hold
100,000
– – 0.01% 315
2017
Q4 		$199K Hold
100,000
– – 0.01% 345
2017
Q3 		$324K Hold
100,000
– – 0.02% 254
2017
Q2 		$318K Buy
+100,000
New +$283K 0.02% 260
2013
Q3 		– Sell
-120,000
Closed -$499K – 141
2013
Q2 		$499K Buy
+120,000
New +$464K 0.07% 62

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ballentine Partners's ATRS Position: Q4 2018 in Review

Ballentine Partners sold out of Antares Pharma, Inc. (ATRS) in Q4 2018, closing a stake of 100,000 shares — an estimated $336K sold.

Ballentine Partners first reported a position in ATRS in Q2 2013 and held it in 7 quarters. The position peaked at $499K in Q2 2013. 120 funds tracked by Wall St. Rank hold ATRS as of Q4 2018.

  • Ballentine Partners reported no remaining Antares Pharma, Inc. position as of Q4 2018 after selling out during the quarter.
  • Ballentine Partners sold 100,000 Antares Pharma, Inc. shares in Q4 2018, an estimated $336K.
  • Ballentine Partners first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 7 quarters.
  • Ballentine Partners's Antares Pharma, Inc. position peaked at $499K in Q2 2013.
  • 120 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2018.

Based on Ballentine Partners's 13F filing for Q4 2018, filed 4 Feb 2019.